Early research is not the same as treatment access
The September 15 briefing separates investigational lung cancer treatment and planned gene-editing trials from care that patients can book.
Three things to know
Leads Biolabs reported phase II results for opamtistomig with chemotherapy. The briefing describes a small group and short follow-up, with immature overall survival data; response rates do not establish long-term benefit.
Cellectis announced plans for early human studies in China. At the time of the briefing, the two programs remained preclinical, with hospitals, recruitment and international-patient eligibility unconfirmed.
An application for one indication does not approve another use. Track approved treatment and research participation separately, including the study location, eligibility and follow-up arrangements.
This is a dated video briefing. Reports and availability may have changed since it was recorded; confirm current details before making plans.